Enanta Pharmaceuticals Stock Return On Asset
| ENTA Stock | USD 9.34 0.03 0.32% |
Enanta Pharmaceuticals fundamentals help investors to digest information that contributes to Enanta Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Enanta Stock. The fundamental analysis module provides a way to measure Enanta Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enanta Pharmaceuticals stock.
The current year's Return On Assets is expected to grow to -0.32. Enanta | Return On Asset |
Enanta Pharmaceuticals Company Return On Asset Analysis
Enanta Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Enanta Pharmaceuticals Return On Asset | -0.17 |
Most of Enanta Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enanta Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enanta Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Enanta Pharmaceuticals is extremely important. It helps to project a fair market value of Enanta Stock properly, considering its historical fundamentals such as Return On Asset. Since Enanta Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enanta Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enanta Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Enanta Total Assets
Total Assets |
|
Based on the latest financial disclosure, Enanta Pharmaceuticals has a Return On Asset of -0.1718. This is 98.04% lower than that of the Biotechnology sector and 99.27% lower than that of the Health Care industry. The return on asset for all United States stocks is 22.71% higher than that of the company.
Enanta Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enanta Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics of similar companies.Enanta Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Enanta Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Enanta Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Enanta Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Enanta Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.60) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 18.38 M | ||||
| Shares Outstanding | 21.19 M | ||||
| Shares Owned By Insiders | 6.00 % | ||||
| Shares Owned By Institutions | 94.00 % | ||||
| Number Of Shares Shorted | 3.44 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 1.32 X | ||||
| Price To Sales | 2.75 X | ||||
| Revenue | 79.2 M | ||||
| Gross Profit | 86.16 M | ||||
| EBITDA | (123.48 M) | ||||
| Net Income | (133.82 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 26.51 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 7.03 X | ||||
| Cash Flow From Operations | (103.15 M) | ||||
| Short Ratio | 20.91 X | ||||
| Earnings Per Share | (5.45) X | ||||
| Target Price | 19.63 | ||||
| Number Of Employees | 145 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 197.9 M | ||||
| Total Asset | 462.27 M | ||||
| Retained Earnings | (207 M) | ||||
| Working Capital | 360 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
| Net Asset | 462.27 M |
About Enanta Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enanta Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enanta Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enanta Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Enanta Pharmaceuticals Piotroski F Score and Enanta Pharmaceuticals Altman Z Score analysis. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (5.45) | Revenue Per Share 3.407 | Quarterly Revenue Growth (0.05) | Return On Assets (0.17) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.